Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Written informed consent or assent~* Confirmed diagnosis of CF~* History of chronic infection with Pseudomonas aeruginosa~* Sputum culture positive for Pseudomonas aeruginosa at Screening~* FEV1 ≥ 25% of predicted value at Screening~Key Exclusion Criteria:~* FEV1 \<25% of predicted at Screening~* History of major complications of lung disease within 8 weeks prior to Screening~* Hemoptysis of ≥60 mL in a 24-hour period within 4 weeks prior to Screening~* History of positive culture for Burkholderia cepacia within 2 years prior to Screening~* History of pulmonary tuberculosis or non-tuberculous mycobacterial lung disease treated within 2 years prior to Screening or requiring treatment at the time of screening~* History of Allergic Broncho-Pulmonary Aspergillosis or any other condition requiring systemic steroids at a dose ≥ equivalent of 10 mg/day of prednisone within 3 months prior to Screening~* Presence of any clinically significant cardiac disease~* History of lung transplantation~* Daily, continuous oxygen supplementation or nighttime supplemental oxygen requirement of greater than 2 L/min~* Administration of any investigational products within 8 weeks prior to study Day 1~* Smoking tobacco or any substance within 6 months prior to screening or anticipated inability to refrain from smoking throughout the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arikayce™ (Type: EXPERIMENTAL): Arikayce™ is liposomal amikacin for inhalation
- TOBI® (Type: ACTIVE_COMPARATOR): TOBI® is tobramycin inhalation solution

Based on this trial design, predict the completion outcome and termination type (if applicable).